Ahead of Oxford Global’s R&D Series Drug Discovery Summit on 26-27 May 2019 in Berlin, Germany, Oxford Global spoke to Torsten Hoffmann of Taros Chemicals about his work in Pharmaceutical R&D and the opportunities and challenges in Drug Discovery…
Read more
I3-STM dealt with a new, tailor-made immunotherapeutic approach using small antibody mimetics synthesized for the therapy of triple-negative breast cancer (TNBC), which is still insufficiently treated with the classic methods. These drugs consist of components that stimulate the immune system and…
Taros’ CEO invited to speak on the exclusive Podcast of the XPOMET© Medicinale in Berlin, 10 – 12 Oct 2019. In the light of Dimitrios presenation at the XPOMET© Medicinale, he was invited to give a pre-talk about his opinion on the transformation of the drug discovery process and his activities to contribute to that…
ZeCardio Therapeutics (ZeCardioTx), a pharma company focused on the discovery of cardiovascular drugs using the zebrafish model and a proprietary screening platform, ZeCardio®, selected Taros’ SVP Drug Discovery, Dr. Torsten Hoffmann, to join…
Starting from a recently identified endogenous inhibitor of vascular calcifications, Taros Drug Discovery scientists will be working in close collaboration with the Lead Discovery Center (LDC) in Dortmund and the Institute for…
ZeClinics SL, a biotech firm focused on preclinical services with zebrafish, announced today that they have entered into a joint research agreement with Taros Chemicals GmbH, a company specializing in drug discovery and medicinal chemistry research, to develop novel therapies for…
